ライフサイエンスコーパス: second-line

1 At second line, a total of 16 patients received a fluoropyr

2 of checkpoint inhibitors in the treatment of second-line advanced NSCLC.

3 lid also covers Nocardia well and could be a second line agent.

4 of sarcoidosis were less likely to require a second-line agent (4.3% vs. 16.2%, P = 0.011).

5 ed by the competitive inhibitor reserpine, a second-line agent to treat hypertension, and by the nonc

6 nd 96.2%) and valganciclovir (23.1%) and the second-line agent was foscarnet (73.1% and 84.6%).

7 iclovir as first-line agent and foscarnet as second-line agent.

8 teral sensitivities, and then using these as second-line agents.

9 This second line also develops SCC indistinguishable from the

10 nt-to-treat population, 414 (69.9%) received second-line and 256 (43.2%) received third-line therapy.

11 w challenged by the use of rituximab both as second-line and as first-line therapy.

12 atic germ cell tumor (GCT) can be cured with second-line and even third-line regimens.

13 -$27 000, vs $28 000 and $25 000 for current second-line and first-line regimens.

14 ls on first-line treatment, and 29 trials on second-line and subsequent treatment.

15 es (18%), including 3% of first-line, 18% of second-line, and 31% of third- or greater line samples.

16 pilepticus, rather than additional trials of second-line anti-epileptic drugs, to avoid neuronal inju

17 ing number of strains fail to respond to the second-line antibiotic azithromycin(3).

18 Second-line antiretroviral therapy (ART) based on ritona

19 ciency virus (HIV)-infected children failing second-line antiretroviral therapy (ART) have no access

20 WHO-recommended second-line antiretroviral therapy (ART) of a pharmacolo

21 For second-line antiretroviral therapy, WHO recommends a boo

22 or ritonavir-boosted lopinavir plus NRTI for second-line antiretroviral therapy.

23 under the assumption of universal access to second-line antiretroviral therapy.

24 that reduces the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug

25 utations to predict resistance to first- and second-line antituberculosis drugs and validated our pre

26 ll or nearly all conventional first-line and second-line antituberculosis drugs.

27 Given the low potency of many second-line antituberculous drugs, we hypothesized that

28 d pelvic floor rehabilitation represented a "second line" approach.

29 constructed a cohort of patients switched to second-line ART (1 January 2003 through 31 December 2008

30 a published open-label, randomised trial of second-line ART (EARNEST) in sub-Saharan Africa.

31 2.6, 95% CI 2.5-2.8; p<0.0001) and switch to second-line ART (HR 5.2, 4.4-6.1; p<0.0001]) compared wi

32 Overall, 67 (6%) switched to second-line ART and 54 (4%) died.

33 Overall, few patients switched to second-line ART and switching happened late in the absen

34 e drug levels were at higher risk of failing second-line ART and thus should be closely monitored.

35 Adaptive VL achieved an ICER <1x GDP if second-line ART and VL costs simultaneously decreased to

36 use mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using

37 5 eligible patients, 10,352 (3%) switched to second-line ART during 782 ,412 person-years of follow-u

38 onitoring of first-line ART and switching to second-line ART in sub-Saharan Africa.

39 the randomised open-label SECOND-LINE trial, second-line ART NtRTI selection was made by either genot

40 Second-line ART regimens were based on ritonavir-boosted

41 resistance and nonadherence on switching to second-line ART requires clarification.

42 The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23),

43 Switches to second-line ART were reported scarcely.

44 nitiating protease inhibitor (PI)-containing second-line ART within the Program for HIV Prevention an

45 7 644 received first-line ART, 1476 received second-line ART, and 1810 received both.

46 he risk of virological failure and switch to second-line ART.

47 n retention, and no viral load monitoring or second-line ART.

48 luded if they received >180 days of PI-based second-line ART.

49 T and 101 weeks (IQR 51-178) for patients on second-line ART.

50 ct NRTI activity in protease inhibitor-based second-line ART.

51 s underscore the need for expanded access to second-line ART.

52 erminant of virological failure in people on second-line ART.

53 ment of >/=1000 copies per mL) and switch to second-line ART.

54 ghting the value of viral load monitoring of second-line ART.

55 We assessed drug survival of second-line biologic therapies and estimated the risk of

56 Little is known about the drug survival of second-line biologic therapies for psoriasis in routine

57 pport clinical decision making when choosing second-line biologic therapy for patients with psoriasis

58 Area and Severity Index at switching to the second-line biologic therapy were predictors of overall

59 -based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this po

60 emoglobin </= 11.0 g/dL, receiving first- or second-line chemotherapy for metastatic breast cancer, w

61 Second-line chemotherapy for patients with oesophagogast

62 We also analysed the second-line chemotherapy.

63 ide reverse-transcriptase inhibitors (NRTIs) second-line combination after 144 weeks of follow-up in

64 inhibitor plus raltegravir as an alternative second-line combination.

65 Patient cohorts included second-line CP CML (n = 286), third-/fourth-line CP CML

66 biologic therapies and decreased over time; second-line discontinuation because of adverse events wa

67 ld benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.

68 Second-line dovitinib in FGFR2(mut) and FGFR2(non-mut) a

69 [81%]) and one-third had resistance to >/=1 second-line drug (24/73 tested).

70 re ineligible for the new regimen because of second-line drug resistance, we projected a change in in

71 to expand treatment access, and the role of second-line drug resistance.

72 to expand treatment access, and the role of second-line drug resistance.

73 For the second-line drug streptomycin (STR), overall concordance

74 on-recommended 5-drug regimen while awaiting second-line drug-susceptibility test (DST) results.

75 with susceptibility, for all first-line and second-line drugs for tuberculosis.

76 ority of phenotypic resistance to first- and second-line drugs in MDR and XDR-TB.

77 rst-line and interferon-alfa and busulfan as second-line drugs of choice.

78 nd optimal treatment, particularly for toxic second-line drugs such as D-cycloserine.

79 (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as wel

80 ST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients wi

81 hat required extended therapy and the use of second-line drugs.

82 erculosis using tailored regimens containing second-line drugs.

83 for first-line drugs and 32 days sooner for second-line drugs.

84 -tuberculosis patients, only 44.7% (596) had second-line DST for both fluoroquinolones and second-lin

85 We quantified the second-line DST results time and proportion of patients

86 time from specimen collection to phenotypic second-line DST results.

87 Median time to second-line DST was 53 days (range, 8-259).

88 Of the 252 patients with complete second-line DST, 101 (40.1%) potentially initiated a sub

89 The second line expresses APP(KM670/671NL)/PSEN1(Deltaexon9)

90 Data on second-line failure and development of protease inhibito

91 e III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the

92 mucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irino

93 weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concen

94 state cancer, with no more than two previous second-line hormonal therapies, and a castrate concentra

95 gen deprivation therapy, most men respond to second-line hormonal therapies.

96 Second-line hormonal therapy (eg, antiandrogens, CYP17 i

97 This PCO addresses second-line hormonal therapy for chemotherapy-naive men

98 However, guidelines have neither addressed second-line hormonal therapy for nonmetastatic CRPC nor

99 fliximab and adalimumab can be considered as second-line immunomodulatory agents for the treatment of

100 5% required oral steroids and 13.8% required second-line immunosuppression.

101 Forty-five (61%) patients received second-line immunotherapy (cyclophosphamide, rituximab,

102 lgesic (49.1% of patients); opiates are the "second line" in 31.5% of patients; however, 33% patients

103 A second line included these 17 putative sites plus the fi

104 -for-age z score < -2 standard deviations at second-line initiation (aHR, 2.8; P = .03), and undetect

105 ctable drug levels within 6 months following second-line initiation (aHR, 4.5; P < .001).

106 nge [IQR], 1.4-3.3 years), and median age at second-line initiation was 10.7 years (IQR, 6.3-13.4 yea

107 he risk of treatment failure 24 months after second-line initiation was 41%.

108 h resistance to both a fluoroquinolone and a second-line injectable (XDR).

109 least 5 likely effective drugs (including a second-line injectable and a fluoroquinolone) used for a

110 ST results for at least fluoroquinolones and second-line injectable drugs, and not having extensively

111 oroquinolone-resistant multidrug resistance, second-line injectable-resistant multidrug resistance, a

112 econd-line DST for both fluoroquinolones and second-line injectable: 55.8% (466 of 835) in the Wester

113 mycobacterials, including first-line agents, second-line injectables, fluoroquinolones, and World Hea

114 lates resistant to fluoroquinolones (Fqs) or second-line injectables.

115 cond-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-base

116 ma, first-line PEM every 3 weeks followed by second-line IPI or first-line NIVO followed by second-li

117 Results PEM every 3 weeks followed by second-line IPI was both more effective and less costly

118 Second-line LA-ART and first-line LA-ART became cost-eff

119 for patients with multiple ART failures; (2) second-line LA-ART for those failing first-line therapy;

120 e analysis; 32% received T-DM1 as first- and second-line line therapy, and 48% received it as fourth-

121 nce supports alternatives to splenectomy for second-line management of patients with persistently low

122 ts remain excellent candidates for first and second-line medical therapies.

123 Epinephrine is life-saving in anaphylaxis; second-line medications (including antihistamines and gl

124 51 (74%) and 18 (26%) treated in first- and second-line metastatic settings, respectively.

125 Second, 6 second-line new agents have been recently developed and

126 s in patients with CRPC receiving first- and second-line NHT and, to the best of our knowledge, is th

127 ohort (and separately for the first-line and second-line NHT cohorts) were best for CTC- patients, in

128 1 through October 2015, 38 patients received second-line nintedanib plus docetaxel.

129 also separately examined the first-line and second-line novel hormonal therapy (NHT) settings.

130 culated the predicted activity of prescribed second-line NRTIs.

131 income settings for the purpose of selecting second-line NRTIs.

132 hods because of progression of disease after second-line OAC, particularly if vitreous seeds are pres

133 ay epithelial basal cells, which serves as a second line of airway epithelial defense that is induced

134 In addition, Tyr-92 was identified as a second line of defense to maintain the position of Phe-1

135 analyses of 37 orangutan genomes provided a second line of evidence.

136 llow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000

137 atment for tuberculosis, and preservation of second line options.

138 d rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in pati

139 following a complete or partial response to second-line or later platinum-based chemotherapy.

140 ol-defined population (patients who received second-line or later treatment); safety was also assesse

141 stigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with adv

142 this randomised trial, vorinostat given as a second-line or third-line therapy did not improve overal

143 to investigate whether vorinostat given as a second-line or third-line therapy improved patients' ove

144 aemia in complete or partial remission after second-line or third-line treatment.

145 tries and randomly assigned (1:1) to receive second-line oral buparlisib (100 mg once daily) or place

146 Second-line oral treatments recommended include an opioi

147 Safe, efficacious, second-line pharmacological treatment options exist for

148 Results of the 96 week SECOND-LINE randomised trial showed that NtRTI-sparing A

149 It is important to identify risk factors for second-line regimen failure.

150 tor with NRTIs remains the best standardised second-line regimen for use in programmes in resource-li

151 ad >400 copies/mL after at least 6 months on second-line regimen or death.

152 A total of 111 children started a PI-based second-line regimen, including 59 girls (53%).

153 promote adherence and timely switching to a second-line regimen.

154 Providing second-line regimens and shifting treatment providers to

155 nd middle-income countries increasingly need second-line regimens with boosted protease inhibitors.

156 motherapy in the neoadjuvant and adjuvant or second-line setting compared with more widely adopted re

157 In the second-line setting, recommendations include docetaxel,

158 ials evaluating checkpoint inhibitors in the second-line setting, three of which were randomized tria

159 n the treatment of metastatic disease in the second-line setting.

160 val for erlotinib versus chemotherapy in the second-line setting.

161 ncer, there is no established therapy in the second-line setting.

162 m(2) days 1, 8, and 15 every 28 days) in the second-line setting.

163 s studied in urothelial carcinoma are in the second-line setting; new targets include CD105, polo-lik

164 emental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer tre

165 his high-risk disease in both first-line and second-line settings.

166 of a planned interim analysis of a trial in second-line SQ NSCLC (CM017) that demonstrated an overal

167 Previous prognostic models for second-line systemic therapy in patients with metastatic

168 sed study, we analysed patients who received second-line targeted therapy for metastatic renal cell c

169 The IMDC prognostic model in the second-line targeted therapy setting has an improved pro

170 Median overall survival since the start of second-line targeted therapy was 12.5 months (95% CI 11.

171 2012, we included 1021 patients treated with second-line targeted therapy.

172 ents for overall survival since the start of second-line targeted therapy.

173 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides

174 n modest but consistent; however, gains from second-line therapies have been disappointing.

175 high-risk patients for closer monitoring and second-line therapies, as well as low-risk patients who

176 involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, an

177 p alternative first-line regimens and better second-line therapies.

178 months, but patients are rarely switched to second-line therapies.

179 AR drug may be used as an alternative second line therapy for treating HER2 + BC.

180 Ninety-two patients (35%) needed second-line therapy after a median of 49 months.

181 Patients with AL amyloidosis who need second-line therapy after response to up-front treatment

182 by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients

183 31%; and (5) suboptimal response to ASCT and second-line therapy as consolidation, 4%.

184 s, VEGF receptors, PDGFR-beta, and c-KIT, as second-line therapy both in patients with FGFR2-mutated

185 ment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC).

186 etinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC.

187 r receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma

188 reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence

189 The drug also has been approved as second-line therapy for polycythemia vera (PV).

190 Corticosteroids are a second-line therapy for those who do not respond, are in

191 wo hundred patients potentially eligible for second-line therapy had a PSS of 5.3 (4.6-7.1) months, w

192 tients with organ progression at the time of second-line therapy had inferior survival.

193 l survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients

194 observed therapy would improve outcomes with second-line therapy in HIV-infected patients for whom fi

195 Hypoglossal nerve stimulation is a useful second-line therapy in patients who cannot tolerate cont

196 Purpose The standard of care for second-line therapy in patients with advanced pancreatic

197 maintenance therapy after chemotherapy-based second-line therapy in patients with chronic lymphocytic

198 ll be used in up to 2 million individuals as second-line therapy in sub Saharan Africa by 2020.

199 and/or when treatment was given as first- or second-line therapy in the metastatic setting.

200 .8% of all patients who received any sort of second-line therapy in the TMZ arm.

201 b could be considered a standard of care for second-line therapy in this post-hydroxyurea patient pop

202 Splenectomy is usually proposed when a second-line therapy is needed.

203 pean centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in

204 , had a shorter survival after initiation of second-line therapy on univariate, but not on multivaria

205 The median time from ASCT to second-line therapy was 24.3 months.

206 Second-line therapy was administered for a median durati

207 % CI, 0.55 to 0.88; P = .0021) from start of second-line therapy were longer in patients in arm A com

208 hree hundred three patients received HDCT as second-line therapy with a 2-year PFS of 63% (95% CI, 57

209 rapy (with at least a partial response after second-line therapy); had received a purine analogue, be

210 omisation was stratified by age, response to second-line therapy, and prognostic factors.

211 As second-line therapy, fulvestrant should be administered

212 For second-line therapy, gemcitabine plus NAB-paclitaxel sho

213 As second-line therapy, he received interferon alfa-2b (IFN

214 To be a viable option for first- or second-line therapy, however, its cost must approach tha

215 subsequent treatment, with special focus on second-line therapy, in the FIRE-3 trial (FOLFIRI plus c

216 When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologi

217 rved in 22% and 12% of patients who received second-line therapy, respectively.

218 As second-line therapy, splenectomy and Rituximab are both

219 examethasone independently prolonged time to second-line therapy.

220 ming virological failure before switching to second-line therapy.

221 d Drug Administration of PD-1 inhibitors for second-line therapy.

222 ent treatment with nilotinib or dasatinib as second-line therapy.

223 ear or less, and progressive disease despite second-line therapy.

224 failure of these drugs; there is no approved second-line therapy.

225 irst-line setting and anetumab ravtansine as second-line therapy.

226 ained efficacy in BRAF(V600E)-mutated ECD as second-line therapy.

227 mproved patient counseling and selection for second-line therapy.

228 was overall survival since the initiation of second-line therapy.

229 to evaluate the efficacy of CA as first- or second-line therapy.

230 ay influence clinician and patient choice of second-line therapy.

231 t-line therapy, or tramadol or duloxetine as second-line therapy.

232 cythaemia vera without splenomegaly who need second-line therapy.

233 ore effective than either alone and provides second line treatment for those with rhinitis poorly con

234 on (AF) has emerged as a widespread first or second line treatment option.

235 rognostic factor for treatment failure after second-line treatment (HR, 1.2 per 10 years; 95% CI, 1.2

236 or metastatic urothelial carcinoma receiving second-line treatment and warrants further investigation

237 axane for first-line treatment and T-DM1 for second-line treatment are recommended.

238 Responses to second-line treatment are uncommon.

239 al photopheresis (ECP) is considered a valid second-line treatment for acute and chronic graft versus

240 oint blockers have recently been approved as second-line treatment for advanced non-small-cell lung c

241 nib is an oral angiokinase inhibitor used as second-line treatment for non-small cell lung cancer.

242 tment for BRAF and NRAS mutant melanomas and second-line treatment for patients who develop resistanc

243 xel, and could be regarded as a new standard second-line treatment for patients with advanced gastric

244 versible EGFR tyrosine kinase inhibitor), as second-line treatment for patients with advanced squamou

245 rvival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic color

246 nation with paclitaxel could be an effective second-line treatment for patients with platinum-pretrea

247 al impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursode

248 ment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa.

249 nd efficacy of amrubicin versus topotecan as second-line treatment for SCLC.

250 1 phototherapy may be considered a potential second-line treatment for VLS.

251 l photopheresis is confirmed as an effective second-line treatment in both aGVHD and cGVHD, because i

252 -receptor agonists (TPO-RAs) is an effective second-line treatment in immune thrombocytopenia (ITP).

253 Regarding second-line treatment in patients who received first-lin

254 vatinib, everolimus, or their combination as second-line treatment in patients with metastatic renal

255 ty of afatinib compared with methotrexate as second-line treatment in patients with recurrent or meta

256 pective cohort study was conducted to assess second-line treatment initiation and treatment delay amo

257 with steroid-refractory disease, response to second-line treatment is dismal.

258 Radiotherapy can be used as a second-line treatment modality.

259 rinotecan with or without bevacizumab in the second-line treatment of metastatic colorectal cancer.

260 added to systemic therapy in the first- and second-line treatment of patients with colorectal liver

261 ce exists to support the use of nivolumab as second-line treatment of patients with squamous advanced

262 ucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.

263 have greater efficacy than paclitaxel in the second-line treatment of urothelial cancers.

264 ocarcinoma have a poor prognosis and limited second-line treatment options.

265 in the post-implementation group initiated a second-line treatment regimen more rapidly than those in

266 We observed that splenectomy for ITP second-line treatment was more effective than Rituximab

267 cin or levofloxacin within triple therapy as second-line treatment were associated with greater effec

268 Second-line treatment with ramucirumab did not significa

269 Second-line treatment with rituximab leads to response r

270 Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received L

271 servation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pe

272 FFS was defined by the absence of second-line treatment, nonrelapse mortality, and recurre

273 ffectiveness than bismuth-based therapy as a second-line treatment, while bismuth-based therapy achie

274 med RR-TB and those reported to have started second-line treatment.

275 6 Italian centers, were submitted to ECP for second-line treatment.

276 ternative that is often, but not always, the second-line treatment.

277 ontrolled, phase 3 studies of first-line and second-line treatment.

278 l cancer who may benefit from gefitinib as a second-line treatment.

279 order of hormonal therapies for CRPC beyond second-line treatment.

280 ll consecutive patients who underwent an ITP second-line treatment: Rituximab or splenectomy.

281 hlorambucil, or alemtuzumab as first-line or second-line treatment; and had an Eastern Cooperative On

282 ed with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly impro

283 that ruxolitinib is not superior to current second-line treatments for ET.

284 ines Agency-should be preferentially used as second-line treatments in these patient populations, typ

285 ecomes more common, especially as first- and second-line treatments, immunotoxicity and autoimmunity

286 Second-line treatments, including hypomethylating agents

287 ves should be used (prescribed) as first- or second-line treatments, though a consensus agreed that b

288 rding which patients will benefit from which second-line treatments.

289 is inadequately treated with first-line and second-line treatments.

290 outcome after ESA failure and the effect of second-line treatments.

291 n may help to improve patient management and second-line trial design.

292 As part of the randomised open-label SECOND-LINE trial, second-line ART NtRTI selection was m

293 As; and (3) effects on OS were much lower in second-line trials (median [interquartile range] respons

294 Empiric first and second-line triple treatments have unacceptable eradicat

295 hole-genome sequencing, encode resistance to second-line tuberculosis drugs.

296 Second-line use of bevacizumab on progression is more ef

297 by another arm to compare first-line versus second-line use of bevacizumab on progression, performed

298 Second-line VF was frequent in this setting.

299 us (low risk vs high risk), line of therapy (second line vs third line), and anatomic site (pleural v

300 Here, we report and characterize a second line with improved sensitivity (N1IP::Cre(HI)) to